{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
gemcitabine
to a specific field?
Status:
Possibly Marketed Outside US
Source:
Cellapy Haircell Meso Tonic by Gm Holdings Co., Ltd
(2016)
Source URL:
First approved in 2014
Source:
Dr. Cellapy SR Premium Solution by GM Holdings Co., Ltd
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Cytosine is a pyrimidine nucleobase, one of the five main bases of nucleic acids. In DNA and RNA cytosine is paired with guanine. Only small amounts of cytosine administered with food are incorporated in DNA. The majority of cytosine is synthesized de-novo starting from carbamoyl phosphate.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
LY2334737 an orally active amide prodrug of gemcitabine, a nucleoside analog chemotherapeutic with a broad spectrum of anti-tumor activity against several human malignancies including pancreatic, ovarian, lung, breast, and bladder. LY2334737 was developed to be absorbed intact and cleaved in vivo, releasing gemcitabine and valproic acid to achieve prolonged systemic exposure, good efficacy with lower toxicity along with added flexibility of administration and greater patient convenience. The hydrolysis and pharmacokinetics of LY2334737 and its downstream metabolites was evaluated in preclinical in vitro and in vivo experiments in mice, rats, and dogs, which demonstrated the prodrug is absorbed largely intact across the intestinal epithelium and delivers LY2334737 to systemic circulation. The hydrolysis of LY2334737 is relatively slow, resulting in sustained release of gemcitabine in vivo. A major enzyme involved in the hydrolysis of LY2334737 is carboxylesterase 2 (CES2). The compound has entered clinical trials and is being evaluated as a potential new anticancer agent.
Status:
Investigational
Source:
NCT02957266: Phase 3 Interventional Unknown status Cervical Cancer
(2015)
Source URL:
Class:
PROTEIN
